# US 2003/0224398 A1 · Purification of the leading front of migratory cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224398 A1
- Document ID: US20030224398A1
- Status: Published application
- Kind: A1
- Application number: 10/365,961
- Filed: 2003-02-12
- Published: 2003-12-04
- Earliest claimed: 2002-02-13
- Inventors: Richard L. Klemke
- Web page: https://patentgrep.com/patent/US20030224398A1

## CPC

- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- A61K 31/739: Lipopolysaccharides
- G01N 33/567: utilising isolate of tissue or organ as binding agent
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates generally to methods of modulating cell migration. Included in the methods of the invention are methods of identifying the state of a pseudopodium in cell migration and methods of inducing extension or retraction of a pseudopodia from a cell. The invention also relates to methods of screening for and identifying an agent effective in inducing extension or retraction of a pseudopodium and therefore affecting cell migration. Agents that can modulate cell migration are useful in treatment of conditions in which cell migration plays a role. Such conditions can include wound healing, angiogenesis, and metastasis of a disease from one location to another. Additionally, the invention provides methods of biochemically separating the pseudopodium of a cell from the remainder of the cell body and methods of determining the proteins present in the pseudopodium and cell body. The invention also includes a pseudopodium isolated by the methods of the invention.

## Claims

### Claim 1

A method of isolating a pseudopodium of a cell, comprising:
a) placing a population of cells on a porous membrane;
b) stimulating the cells with a chemoattractant on the opposite side of the membrane from where the cells are placed, such that at least one cell is stimulated to extend a pseudopodium through the pores of the porous membrane, leaving a cell body on the porous membrane; and
c) removal of the pseudopodia extending through the pores of the porous membrane.

### Claim 2 (depends on 1)

The method of claim 1, further comprising identifying the proteins of the removed pseudopodia.

### Claim 3 (depends on 1)

The method of claim 1, further comprising removal of the cell bodies remaining on the surface of the porous membrane.

### Claim 4 (depends on 3)

The method of claim 3, further comprising identifying the proteins of the removed cell bodies.

### Claim 5 (depends on 1)

The method of claim 1, wherein the porous membrane is a porous polycarbonate membrane.

### Claim 6 (depends on 1)

The method of claim 1, wherein the chemoattractant is lysophosphatidic acid (LPA).

### Claim 7 (depends on 1)

The method of claim 1, wherein removal of the pseudopodia extending through the pores of the porous membrane is performed with a cotton swab.

### Claim 8 (depends on 1)

A pseudopodium isolated by the method of claim 1.

### Claim 9

A method of inducing extension of a pseudopodia from a cell, comprising:
a) placing a population of cells on a porous membrane; and
b) stimulating the cells with a chemoattractant on the opposite side of the membrane from where the cells are placed, such that at least one cell is stimulated to extend a pseudopodium.

### Claim 10 (depends on 9)

The method of claim 9, wherein the chemoattractant is lysophosphatidic acid (LPA).

### Claim 11

A method of inducing retraction of a pseudopodia from a cell, comprising:
a) placing a population of cells on a porous membrane; and
b) stimulating the cells with a chemoattractant on both sides of the membrane, such that at least one cell is stimulated to retract a pseudopodium.

### Claim 12 (depends on 11)

The method of claim 11, wherein the chemoattractant is lysophosphatidic acid (LPA).

### Claim 13

A method of identifying an agent effective in inducing extension or retraction of a pseudopodium comprising:
a) placing a population of cells on a porous membrane;
b) measuring the number of cells that have a pseudopodium extended through the pores of the porous membrane, leaving a cell body on the porous membrane;
c) stimulating cells with an agent on the opposite side of the membrane from where the cells are placed; and
d) measuring the number of cells that are stimulated to extend a pseudopodium through the pores of the porous membrane,
wherein an increase in the number of cells extending a pseudopodium from step b) to step d) is indicative of an agent effective in inducing extension of a pseudopodium and a decrease in the number of cells extending a pseudopodium from step b) to step d) is indicative of an agent effective in inducing retraction of a pseudopodium.

### Claim 14 (depends on 13)

The method of claim 13, further comprising isolating the extended pseudopodia and determining the proteins contained therein.

### Claim 15 (depends on 13)

The method of claim 13, wherein the agent increases the number of cells extending a pseudopodium.

### Claim 16 (depends on 15)

The method of claim 15, wherein the agent stimulates at least about 90% of the cells to extend a pseudopodium.

### Claim 17 (depends on 13)

The method of claim 13, wherein the agent decreases the number of cells extending a pseudopodium.

### Claim 18 (depends on 13)

A method of modulating cell migration comprising administering an effective amount of an agent identified by the method of claim 13, wherein the agent is effective in inducing extension or retraction of a pseudopodium.

### Claim 19 (depends on 13)

A method of modulating a cell migration-associated process comprising administering an effective amount of an agent identified by the method of claim 13, wherein the agent is effective in modulating the cell migration-associated process.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cell migration-associated process is selected from cell and tissue development, wound healing, immune responses, angiogenesis, embryonic development, metastases, neuronal regeneration, stem cell migration, and inflammation.

### Claim 21

A method of modulating cell migration comprising administration of a composition that induces extension or retraction of a pseudopodium, thereby modulating cell migration.

### Claim 22

A method of identifying the state of a pseudopodium comprising measuring the level of Rac or Cdc42 in an isolated pseudopodium, wherein an increase in Rac or Cdc42 activity in the pseudopodium is indicative a state of extension of the pseudopodium and wherein a decrease of Rac or Cdc42 activity in the pseudopodium is indicative of a state of retraction of the pseudopodium.

### Claim 23

A method of modulating cell migration comprising administration of an agent that regulates actin polymerization or depolymerization.

### Claim 24

A method of modulating cell migration comprising administration of an agent that regulates myosin contractility.

### Claim 25

A method of modulating cell migration comprising administration of an agent that regulates adhesive signals that facilitate attachment or detachment of a membrane to an extracellular matrix (ECM).

### Claim 26

A method of identifying proteins specifically expressed in the pseudopodium or specifically expressed in the cell body of a cell during a cell migration-associated process comprising:
a) identifying the proteins expressed in the pseudopodium during migration;
b) identifying the proteins expressed in the cell body during migration; and
c) comparing the proteins expressed in the pseudopodium to the proteins present in the cell body,
wherein the comparing allows identification of proteins similar to the pseudopodium and cell body and wherein a difference in expression is indicative of proteins specifically expressed in the pseudopodium or the cell body.

### Claim 27 (depends on 26)

The method of claim 26, further comprising
i) placing a population of cells on a porous membrane;
ii) stimulating the cells with a chemoattractant on the opposite side of the membrane from where the cells are placed, such that at least one cell is stimulated to extend a pseudopodium through the pores of the porous membrane, leaving a cell body on the porous membrane; and
iii) removal of the pseudopodia extending through the pores of the porous membrane
prior to identifying the proteins in the pseudopodium.

### Claim 28 (depends on 27)

The method of claim 27, further comprising
iv) removal of the cell bodies remaining on the porous membrane
prior to identifying the proteins in the cell body.

### Claim 29 (depends on 26)

The method of claim 26, wherein the comparing is performed by brute force mass spectrometry.

### Claim 30 (depends on 26)

The method of claim 26, wherein the comparing is performed by two dimensional gel electrophoresis.

### Claim 31 (depends on 26)

A method of modulating a cell migration-associated process comprising administering an effective amount of an agent targeted to modulate expression of a protein identified by the method of claim 26.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cell migration-associated process is selected from cell and tissue development, wound healing, immune responses, angiogenesis, embryonic development, metastases, neuronal regeneration, stem cell migration, and inflammation.

### Claim 33

A method of identifying polynucleotides specifically expressed in the pseudopodium or specifically expressed in the cell body of a cell during a cell migration-associated process comprising:
a) identifying the polynucleotides expressed in the pseudopodium during migration;
b) identifying the polynucleotides expressed in the cell body during migration; and
c) comparing the expression in the pseudopodium to the expression in the cell body,
wherein the comparing allows identification of expression of polynucleotides similar to the pseudopodium and cell body and wherein a difference in expression is indicative of polynucleotides specifically expressed in the pseudopodium or the cell body.
